UNICYCIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 USD | -2.80% |
|
-9.96% | +19.86% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 24.39M | Capitalization | 37.19M |
|---|---|---|---|---|---|
| Net income 2024 * | -25M | Net income 2025 * | -28M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.52 x |
| P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-3.4
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.6% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.80% | ||
| 1 week | -9.96% | ||
| Current month | -24.64% | ||
| 1 month | -31.58% | ||
| 3 months | +8.33% | ||
| 6 months | +42.31% | ||
| Current year | +19.86% |
1 week
1.03
1.20
1 month
1.021.60
Current year
0.761.82
1 year
0.471.82
3 years
0.408.73
5 years
0.408.73
10 years
0.408.73
| Managers | Title | Age | Since |
|---|---|---|---|
Shalabh Gupta
CEO | Chief Executive Officer | 51 | 16-08-17 |
John Townsend
DFI | Director of Finance/CFO | 62 | 20-08-31 |
Pramod Gupta
COO | Chief Operating Officer | 63 | 20-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sandeep Laumas
BRD | Director/Board Member | 56 | 17-12-31 |
John Ryan
BRD | Director/Board Member | 80 | 17-12-31 |
Gaurav Aggarwal
BRD | Director/Board Member | 51 | 23-03-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.04 | -2.80% | 179 328 |
| 24-04-23 | 1.07 | -6.96% | 244,227 |
| 24-04-22 | 1.15 | +7.48% | 458,697 |
| 24-04-19 | 1.07 | -1.83% | 231,021 |
| 24-04-18 | 1.09 | -5.63% | 893,190 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.07
USD
Average target price
5.3
USD
Spread / Average Target
+395.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.86% | 37.19M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- UNCY Stock
